Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Pemetrexed Disodium
Generic Name
Pemetrexed Disodium
Active Ingredient
PemetrexedCategory
Folate Analog Metabolic Inhibitor [EPC]
Variants
3
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Pemetrexed Disodium, you must consult a qualified healthcare professional.
| 43598-386 |
Detailed information about Pemetrexed Disodium
Pemetrexed is a folate analog metabolic inhibitor used primarily in the treatment of certain types of lung cancer and mesothelioma. It works by disrupting the metabolic processes essential for cancer cell replication.
The standard dosage of Pemetrexed is calculated based on the patient's Body Surface Area (BSA), which is determined using height and weight.
Mandatory Premedication Regimen:
To reduce toxicity, all patients must follow a specific supplementation schedule:
Pemetrexed is not currently approved for use in pediatric patients. The safety and effectiveness of Pemetrexed in children and adolescents have not been established. Clinical trials in pediatric populations have not demonstrated significant anti-tumor activity for the types of cancers typically treated with this agent in adults.
Dosage adjustments are critical based on kidney function, measured by Creatinine Clearance (CrCl):
Pemetrexed has not been extensively studied in patients with severe hepatic (liver) impairment (bilirubin > 1.5 times the upper limit of normal). However, for patients with mild to moderate hepatic impairment, no specific dose adjustments are typically required, provided renal function remains adequate.
In clinical trials, no overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients. However, because elderly patients are more likely to have decreased renal function, careful monitoring of Creatinine Clearance is essential.
Pemetrexed is administered in a clinical setting (hospital or infusion center) by trained healthcare professionals.
Because Pemetrexed is administered on a strict 21-day cycle by a medical team, a 'missed dose' usually refers to a delayed appointment. If you miss an infusion appointment, contact your oncology clinic immediately to reschedule. Delays may be necessary if your blood counts (white cells, platelets) are too low or if you have not taken your folic acid and B12 supplements correctly.
Signs of a Pemetrexed overdose include severe bone marrow suppression (leading to infection, bleeding, or extreme fatigue), severe skin rashes, and intense gastrointestinal distress (diarrhea, mucositis). In the event of an accidental overdose, treatment is supportive. Healthcare providers may administer leucovorin (folinic acid) as an 'antidote' to help rescue healthy cells from the effects of the drug.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not skip your vitamin supplements, as they are vital for your safety while taking Pemetrexed.
Most patients receiving Pemetrexed will experience some side effects, though the severity is often managed through vitamin supplementation and premedication.
Pemetrexed is a high-alert medication that requires close supervision by an oncologist. The most critical safety aspect of Pemetrexed therapy is the mandatory use of folic acid and vitamin B12. Failure to take these supplements as directed significantly increases the risk of 'Grade 4' toxicities, which are life-threatening. Patients must also be aware that Pemetrexed is specifically for non-squamous lung cancer; it is ineffective and potentially harmful for those with squamous cell histology.
No FDA black box warnings for Pemetrexed. Despite the absence of a boxed warning, the risk of severe bone marrow suppression is the primary clinical concern and is managed through strict adherence to the supplementation protocol and blood count monitoring.
While there are few absolute contraindications for drug combinations with Pemetrexed, the most significant risk involves Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in patients with reduced kidney function.
There are specific circumstances where Pemetrexed must never be used due to the extreme risk of harm:
Pemetrexed is considered highly teratogenic (can cause birth defects or fetal death). According to the FDA, Pemetrexed is classified as a drug that can cause fetal harm when administered to a pregnant woman.
It is not known if Pemetrexed is excreted in human breast milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants, women are advised
Pemetrexed is a multi-targeted antifolate. Its primary mechanism is the inhibition of three enzymes essential for the de novo synthesis of thymidine and purine nucleotides: Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT).
Upon entering the cell via the reduced folate carrier (RFC), Pemetrexed is converted into polyglutamate forms by the enzyme folylpolyglutamate synthetase (FPGS). These polyglutamated forms are significantly more potent inhibitors of TS and GARFT than the parent compound. By blocking these enzymes, Pemetrexed prevents the formation of DNA and RNA, leading to 'thymineless death' and the arrest of the cell cycle in the S-phase. This multi-pathway inhibition makes it harder for cancer cells to develop resistance compared to drugs that target only a single enzyme.
The pharmacodynamic effect of Pemetrexed is dose-dependent. Higher doses lead to greater inhibition of nucleotide synthesis, but also higher toxicity to rapidly dividing healthy cells (like those in the bone marrow and gut). The use of folic acid and B12 shifts the dose-response curve, allowing for effective cancer cell killing while protecting healthy tissues from the most severe 'off-target' effects. The onset of action begins shortly after infusion as the drug is polyglutamated within the cells, but the clinical effect (tumor shrinkage) is usually not visible on scans for several weeks (2-3 cycles).
Common questions about Pemetrexed Disodium
Pemetrexed is primarily used to treat two specific types of cancer: non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. In NSCLC, it can be used as a first-line treatment in combination with other drugs, as a standalone maintenance therapy to keep cancer from returning, or as a second-line treatment if other therapies have failed. For mesothelioma, it is typically used in combination with cisplatin for patients whose cancer cannot be removed by surgery. It is important to note that it is only effective for 'non-squamous' cell types. Your doctor will use a biopsy to determine your specific cancer histology before prescribing this medication.
The most common side effects of Pemetrexed include fatigue, nausea, and loss of appetite. However, the most significant clinical side effect is myelosuppression, which is a decrease in blood cell production by the bone marrow. This leads to low white blood cell counts (increasing infection risk), low red blood cell counts (causing anemia and tiredness), and low platelet counts (increasing the risk of bruising or bleeding). Other frequent issues include skin rashes and mouth sores. To minimize these risks, patients are required to take folic acid and vitamin B12 supplements and dexamethasone. Most side effects are manageable with supportive care and proper premedication.
There is no known direct chemical interaction between Pemetrexed and alcohol, but most oncologists recommend avoiding or strictly limiting alcohol during treatment. Alcohol can cause dehydration, which puts extra strain on the kidneys—the very organs responsible for clearing Pemetrexed from your body. Furthermore, alcohol can irritate the lining of the mouth and digestive tract, which may already be sensitive or sore due to the chemotherapy. Alcohol can also worsen the fatigue and nausea associated with treatment. If you choose to drink, it is vital to discuss it with your healthcare provider to ensure it is safe for your specific situation.
No, Pemetrexed is not safe during pregnancy and can cause severe harm or death to an unborn baby. It is classified as a teratogen, meaning it interferes with normal fetal development. Women of childbearing age must use highly effective birth control during treatment and for at least 6 months after their last dose. Men taking Pemetrexed should also use contraception if their partner could become pregnant, as the drug may damage sperm; this should continue for 3 months after the final dose. If you become pregnant while taking Pemetrexed, you must notify your doctor immediately. Breastfeeding is also discouraged during and for one week after treatment.
Pemetrexed begins working at the cellular level almost immediately after the infusion starts, as it enters cancer cells and begins blocking DNA synthesis. However, visible results, such as the shrinking of a tumor on a CT or PET scan, usually take several weeks to become apparent. Doctors typically evaluate the effectiveness of the treatment after every 2 or 3 cycles (about 6 to 9 weeks). Some patients may notice an improvement in symptoms, such as reduced coughing or better breathing, before the first follow-up scan. It is important to complete the cycles as prescribed by your oncologist to give the medication the best chance to work.
Pemetrexed is not a drug that causes physical dependence, so stopping it suddenly does not cause withdrawal symptoms like some other medications might. However, stopping chemotherapy prematurely can allow the cancer cells to begin growing or spreading again, potentially making the disease harder to treat in the future. If you are experiencing difficult side effects, you should not simply skip an appointment. Instead, talk to your oncologist about your concerns. They may be able to reduce the dose, provide better supportive medications for side effects, or switch you to a different treatment that you tolerate better.
Because Pemetrexed is administered by healthcare professionals in a clinic, a 'missed dose' usually means a missed or delayed appointment. If you cannot make it to your scheduled infusion, contact your oncology office as soon as possible to reschedule. Timing is important in chemotherapy to keep the pressure on the cancer cells, but short delays (a few days) are common if your blood counts are too low or if you have an active infection. Also, if you forget to take your daily folic acid supplement for several days, tell your doctor, as they may need to delay your Pemetrexed infusion to ensure your body is protected from toxicity.
Weight gain is not a typical side effect of Pemetrexed itself; in fact, weight loss is more common due to side effects like nausea, loss of appetite, and changes in taste. However, some patients may experience weight gain or swelling (edema) for other reasons. For example, the steroid dexamethasone, which is given to prevent skin rashes, can cause fluid retention and increased appetite if used long-term. Additionally, fluid accumulation in the chest or abdomen (pleural effusion or ascites) can cause the number on the scale to go up. If you notice sudden weight gain or swelling in your legs, you should report it to your doctor immediately.
Pemetrexed can interact with several other medications, most notably Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen (Advil, Motrin) and naproxen (Aleve). These drugs can slow down the removal of Pemetrexed by the kidneys, leading to dangerously high levels of the chemo in your blood. Other drugs that can affect the kidneys, such as certain antibiotics or gout medications like probenecid, should also be used with caution. Always provide your oncologist with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are taking to avoid potentially life-threatening drug interactions.
Yes, Pemetrexed is available as a generic medication. The original brand-name version, Alimta, lost its patent protection in recent years, allowing several other pharmaceutical companies to produce generic versions. Generic Pemetrexed contains the same active ingredient and must meet the same FDA standards for quality, strength, and purity as the brand-name drug. Using the generic version can significantly reduce the cost of treatment for patients and insurance providers. Your hospital or infusion center will likely use whichever version is currently available in their pharmacy, but the clinical effect and the required vitamin supplementation remain the same.
Other drugs with the same active ingredient (Pemetrexed)
> Warning: Stop taking Pemetrexed and call your doctor immediately if you experience any of these symptoms. These may indicate life-threatening complications.
While many side effects of Pemetrexed resolve after the treatment is completed, some may persist.
There are currently no FDA black box warnings for Pemetrexed. However, the drug carries significant warnings regarding myelosuppression and renal failure that are emphasized in the 'Warnings and Precautions' section of the official prescribing information. The requirement for vitamin supplementation is considered a 'critical safety measure' to prevent the severe toxicities that were observed in early clinical development.
Report any unusual symptoms to your healthcare provider. Keeping a daily log of how you feel can help your oncology team adjust your care plan.
Patients undergoing Pemetrexed treatment require frequent laboratory monitoring:
Pemetrexed can cause significant fatigue and, in some cases, dizziness or 'chemo brain' (cognitive clouding). Patients should observe how the drug affects them before attempting to drive or operate heavy machinery. If you feel excessively tired or weak, avoid these activities.
There is no direct contraindication between alcohol and Pemetrexed; however, alcohol can contribute to dehydration and may irritate the lining of the mouth and throat, worsening mucositis. Alcohol can also put additional strain on the liver. It is generally advised to limit alcohol consumption during chemotherapy.
Pemetrexed does not cause a physical withdrawal syndrome and does not require tapering. However, stopping treatment early can allow the cancer to grow or spread. If you wish to discontinue treatment due to side effects, discuss this with your oncologist, who may suggest a dose reduction or an alternative therapy.
> Important: Discuss all your medical conditions, especially any history of kidney disease or fluid accumulation, with your healthcare provider before starting Pemetrexed.
There are no known direct interactions between Pemetrexed and specific foods. However, the 'interaction' with vitamins is the most important:
Pemetrexed does not typically interfere with the chemical assays used in lab tests, but its biological effects will be reflected in:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any over-the-counter pain relievers like Advil, Aleve, or Motrin.
These are conditions where the doctor must carefully weigh the benefits of the drug against the potential risks:
There is no significant evidence of cross-sensitivity between Pemetrexed and other non-folate chemotherapy agents. However, patients who have had severe reactions to other folate-based drugs (like Methotrexate) should be monitored very closely, as the chemical structures are related, though their specific enzyme targets differ.
> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and any previous reactions to chemotherapy, before prescribing Pemetrexed.
Pemetrexed is not approved for use in children. Clinical trials in pediatric patients with solid tumors (such as osteosarcoma or Ewing sarcoma) did not show enough activity to justify its use. Furthermore, the long-term effects of Pemetrexed on growth and development in children are unknown.
While clinical trials did not show a major difference in how Pemetrexed works in patients over 65 compared to younger patients, the risk of side effects is higher in the elderly. This is primarily because kidney function naturally declines with age. Older adults are more likely to experience severe neutropenia and infections. Close monitoring of renal function and blood counts is paramount in this population.
Renal impairment is the most significant factor in Pemetrexed toxicity.
Pemetrexed is not primarily metabolized by the liver. Patients with mild hepatic impairment (bilirubin ≤ 1.5 x ULN and/or AST/ALT ≤ 3 x ULN) do not typically require dose adjustments. However, Pemetrexed has not been studied in patients with severe liver disease (Child-Pugh Class C), and such patients should be treated with extreme caution.
> Important: Special populations require individualized medical assessment. Always inform your oncology team if you are pregnant, planning to become pregnant, or have any history of kidney or liver disease.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | ~81% (Primarily to Albumin) |
| Half-life | 3.5 hours (Normal renal function) |
| Tmax | End of 10-minute infusion |
| Metabolism | Minimal hepatic; Intracellular polyglutamation |
| Excretion | Renal (70% - 90% unchanged in urine) |
Pemetrexed is classified as a Folate Analog Metabolic Inhibitor. It is part of the broader category of Antimetabolites. Related medications include Methotrexate (an older antifolate) and 5-Fluorouracil (a pyrimidine analog), though Pemetrexed's multi-targeted profile distinguishes it from these agents in the treatment of lung cancer.